CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Absci Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Absci Corp
18105 Se Mill Plain Blvd
Phone: (360) 949-1041p:360 949-1041 VANCOUVER, WA  98683  United States Ticker: ABSIABSI

Business Summary
Absci Corporation is a generative artificial intelligence (AI) drug creation company. The Company combines AI with scalable wet lab technologies to create biologics for patients. It has built an Integrated Drug Creation platform to identify novel drug targets, discover biotherapeutic candidates, and generate the cell lines to manufacture them in a single process. The Company uses its platform to predict, identify, design, construct, screen, select and scale production of biologic drug candidates for its partners, and learn from the data it generates. Its SoluPro technology is a multiplex synthetic biology approach that overcomes the limitations of highest-throughput automation labs. The Company supports its generative AI designs with its wet lab's high-throughput functional validation capabilities. It reconstructs prevalent immune-response molecules, such as antibodies from disease tissue and identify their corresponding antigens, offering new therapeutic targets.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202412/31/2023YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chief Executive Officer, Founder, Director SeanMcclain 34 10/1/2020 8/1/2011
Chief Financial Officer, Chief Business Officer, Treasurer ZachariahJonasson 51 12/31/2023 4/1/2016
Chief Innovation Officer AndreasBusch 60 9/30/2022 3/17/2022
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Totient, Inc. 1 Alewife Center Cambridge MA United States

Business Names
Business Name
Absci d.o.o. Beograd
Absci GmbH
Absci Ltd
6 additional Business Names available in full report.

General Information
Number of Employees: 155 (As of 12/31/2023)
Outstanding Shares: 114,855,759 (As of 10/31/2024)
Shareholders: 56
Stock Exchange: NASD
Federal Tax Id: 453931977
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024